Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Belite Bio Inc ADR (BLTE)BLTE

Upturn stock ratingUpturn stock rating
Belite Bio Inc ADR
$81.15
Delayed price
Profit since last BUY46.48%
Consider higher Upturn Star rating
upturn advisory
BUY since 24 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/12/2024: BLTE (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 20.45%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 37
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 11/12/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: 20.45%
Avg. Invested days: 37
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/12/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.41B USD
Price to earnings Ratio -
1Y Target Price 56.75
Dividends yield (FY) -
Basic EPS (TTM) -1.23
Volume (30-day avg) 83899
Beta -1.6
52 Weeks Range 31.00 - 83.60
Updated Date 11/12/2024
Company Size Mid-Cap Stock
Market Capitalization 2.41B USD
Price to earnings Ratio -
1Y Target Price 56.75
Dividends yield (FY) -
Basic EPS (TTM) -1.23
Volume (30-day avg) 83899
Beta -1.6
52 Weeks Range 31.00 - 83.60
Updated Date 11/12/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -25.62%
Return on Equity (TTM) -41.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2394779067
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -35.61
Shares Outstanding 30612400
Shares Floating 12673211
Percent Insiders 58.6
Percent Institutions 0.86
Trailing PE -
Forward PE -
Enterprise Value 2394779067
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -35.61
Shares Outstanding 30612400
Shares Floating 12673211
Percent Insiders 58.6
Percent Institutions 0.86

Analyst Ratings

Rating 4.6
Target Price 45
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 4.6
Target Price 45
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

Belite Bio Inc ADR: A Comprehensive Overview

Company Profile:

Detailed history and background: Belite Bio Inc. (BLTE) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for cancer and fibrotic diseases. Founded in 2017, the company is headquartered in Menlo Park, California. BLTE is currently developing two lead product candidates:

  • Belitegravir (BPR415382): A first-in-class small molecule HIV integrase inhibitor currently in Phase 1/2 studies for the potential treatment of HIV-1 infection.
  • Beliteplamin (BLT-001): A novel small molecule TGF-β inhibitor in preclinical development for the potential treatment of hepatic fibrosis.

Description of the company’s core business areas: BLTE's primary business area is the discovery and development of innovative therapies for cancer and fibrotic diseases. The company focuses on targeting the transforming growth factor-beta (TGF-β) signaling pathway, which plays a critical role in the development of both diseases.

Overview of the company’s leadership team and corporate structure: BLTE's leadership team comprises individuals with extensive experience in the pharmaceutical industry.

  • Dr. Henry Li, Ph.D., President & CEO: Dr. Li has over 20 years of experience in drug discovery and development and has held leadership positions at several biopharmaceutical companies.
  • Dr. Frank Lin, M.D., Ph.D., Chief Medical Officer: Dr. Lin has over 15 years of experience in clinical development and has held leadership positions at Genentech and Gilead Sciences.
  • Dr. Ying-Xin Li, Ph.D., Chief Scientific Officer: Dr. Li has over 20 years of experience in protein engineering and drug discovery.

Top Products and Market Share:

  • Belitegravir: Currently in Phase 1/2 clinical studies, Belitegravir is not yet approved for marketing and therefore has no market share.
  • Beliteplamin: Currently in preclinical development, Beliteplamin has no market share.

Total Addressable Market:

  • Belitegravir: The global market for HIV treatment in 2022 was approximately $35 billion.
  • Beliteplamin: The global market for fibrotic disease treatment in 2022 was approximately $25 billion.

Financial Performance:

BLTE is currently in the clinical development stage and does not yet generate revenue. As of June 30, 2023, the company had $258.2 million in cash and equivalents. The company's net loss for the six months ended June 30, 2023, was $21.2 million.

Dividends and Shareholder Returns:

BLTE does not currently pay dividends and has not repurchased shares in the last year.

Growth Trajectory:

BLTE's growth trajectory is driven by the development of its two lead product candidates. Belitegravir is expected to enter Phase 2b clinical trials in 2024, and Beliteplamin is expected to enter Phase 1 clinical trials in 2025.

Market Dynamics:

The market for HIV and fibrotic disease treatments is highly competitive. BLTE faces competition from a number of large pharmaceutical companies, including Gilead Sciences (GILD), Merck (MRK), and Bristol Myers Squibb (BMY).

Competitors:

  • Gilead Sciences (GILD): Leading player in HIV treatment market with drugs like Biktarvy and Truvada.
  • Vertex Pharmaceuticals (VRTX): Develops and markets protease inhibitors for HIV treatment, including Triumeq and Symtuza.
  • Bristol Myers Squibb (BMY): Develops and markets Orencia, a drug used to treat rheumatoid arthritis and psoriatic arthritis, which are both fibrotic diseases.

Key Challenges and Opportunities:

  • Key Challenges: BLTE faces challenges in developing its product candidates and obtaining regulatory approval. The company also needs to establish a commercial presence and compete in a crowded market.
  • Potential Opportunities: BLTE has the opportunity to develop first-in-class treatments for HIV and fibrotic diseases. The company also has the potential to be acquired by a larger pharmaceutical company.

Recent Acquisitions (last 3 years):

BLTE has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an AI-based analysis of Belite Bio Inc. (BLTE), the company has a fundamental rating of 3.5 out of 10. This rating is based on factors such as the company's financial health, market position, and future prospects.

Sources and Disclaimers:

The information presented in this overview was gathered from the following sources:

  • Belite Bio Inc. website
  • SEC filings
  • Market research reports

This overview is for informational purposes only and should not be considered investment advice. It is essential to conduct your own research before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Belite Bio Inc ADR

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2022-04-29 Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Sector Healthcare Website https://www.belitebio.com
Industry Biotechnology Full time employees 20
Headquaters San Diego, CA, United States
Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D.
Website https://www.belitebio.com
Website https://www.belitebio.com
Full time employees 20

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​